Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$6.2 million.

  • Myriad Genetics' Cash from Investing Activities fell 18266.67% to -$6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$27.3 million, marking a year-over-year decrease of 5166.67%. This contributed to the annual value of -$11.9 million for FY2024, which is 13730.41% down from last year.
  • Myriad Genetics' Cash from Investing Activities amounted to -$6.2 million in Q3 2025, which was down 18266.67% from -$6.9 million recorded in Q2 2025.
  • Myriad Genetics' Cash from Investing Activities' 5-year high stood at $291.0 million during Q3 2021, with a 5-year trough of -$41.3 million in Q1 2022.
  • In the last 5 years, Myriad Genetics' Cash from Investing Activities had a median value of -$6.2 million in 2025 and averaged $10.3 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first skyrocketed by 160175.44% in 2021, then plummeted by 119090.91% in 2022.
  • Over the past 5 years, Myriad Genetics' Cash from Investing Activities (Quarter) stood at -$25.9 million in 2021, then plummeted by 37.45% to -$35.6 million in 2022, then surged by 66.29% to -$12.0 million in 2023, then skyrocketed by 50.83% to -$5.9 million in 2024, then decreased by 5.08% to -$6.2 million in 2025.
  • Its last three reported values are -$6.2 million in Q3 2025, -$6.9 million for Q2 2025, and -$8.3 million during Q1 2025.